The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells
Sign Up to like & getrecommendations! Published in 2018 at "Archives of Toxicology"
DOI: 10.1007/s00204-018-2229-5
Abstract: Novel therapies are required for the treatment of metastatic renal cell carcinoma (RCC), which is associated with inoperable disease and patient death. Histone deacetylases (HDACs) are epigenetic modifiers and potential drug targets. Additional information on… read more here.
Keywords: carcinoma; deacetylases hdac1; histone deacetylases; renal carcinoma ... See more keywords